Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
LeMaitre Vascular Inc is a medical instruments & supplies business based in the US. LeMaitre Vascular shares (LMAT) are listed on the NASDAQ and all prices are listed in US Dollars. LeMaitre Vascular employs 386 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $42.83 |
|---|---|
| 52-week range | $41.68 - $64.23 |
| 50-day moving average | $49.02 |
| 200-day moving average | $53.31 |
| Wall St. target price | $65.86 |
| PE ratio | 33.243 |
| Dividend yield | $0.425 (1%) |
| Earnings per share (TTM) | $1.33 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $42.83 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-23) | -16.90% |
| 3 months (2021-10-26) | -22.35% |
| 6 months (2021-07-26) | -21.50% |
| 1 year (2021-01-26) | -10.02% |
|---|---|
| 2 years (2020-01-24) | 17.41% |
| 3 years (2019-01-25) | 82.49% |
| 5 years (2017-01-26) | 85.09% |
Valuing LeMaitre Vascular stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LeMaitre Vascular's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LeMaitre Vascular's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, LeMaitre Vascular shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
LeMaitre Vascular's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.005. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LeMaitre Vascular's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
LeMaitre Vascular's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48.4 million.
The EBITDA is a measure of a LeMaitre Vascular's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $152.5 million |
|---|---|
| Operating margin TTM | 24.71% |
| Gross profit TTM | $84.6 million |
| Return on assets TTM | 8.55% |
| Return on equity TTM | 13.54% |
| Profit margin | 18.21% |
| Book value | $11.40 |
| Market capitalisation | $964.8 million |
TTM: trailing 12 months
Dividend payout ratio: 33.33% of net profits
Recently LeMaitre Vascular has paid out, on average, around 33.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), LeMaitre Vascular shareholders could enjoy a 1% return on their shares, in the form of dividend payments. In LeMaitre Vascular's case, that would currently equate to about $0.425 per share.
While LeMaitre Vascular's payout ratio might seem fairly standard, it's worth remembering that LeMaitre Vascular may be investing much of the rest of its net profits in future growth.
LeMaitre Vascular's most recent dividend payout was on 1 December 2021. The latest dividend was paid out to all shareholders who bought their shares by 17 November 2021 (the "ex-dividend date").
Over the last 12 months, LeMaitre Vascular's shares have ranged in value from as little as $41.68 up to $64.2341. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LeMaitre Vascular's is 1.3147. This would suggest that LeMaitre Vascular's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors.
Steps to owning and managing CORZ, with 24-hour and historical pricing before you buy.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.